RBC Capital raised the firm’s price target on Beam Therapeutics (BEAM) to $26 from $22 and keeps a Sector Perform rating on the shares after its Q4 results. On Sickle Cell Disease, the company continues to target BLA submission this year and announces non-dilutive debt deal with Sixth Street to support potential commercialization, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BEAM:
- Beam Therapeutics price target raised to $65 from $57 at Wedbush
- Beam Therapeutics price target raised to $75 from $74 at Canaccord
- Beam Therapeutics: Clinical Momentum, Platform Validation, and De‑Risked Financing Support Buy Rating and $47 Target
- Beam Therapeutics price target raised to $47 from $45 at BofA
- Kyverna Therapeutics appoints Sravan Emany, Andrew Miller to board